Daphne Zohar is the Founder, CEO and Board Member of Seaport Therapeutics. Previously, she was the Founder, CEO and Board Member of PureTech Health, where she also co-founded PureTech’s entities, including Karuna Therapeutics, which was acquired by Bristol Myers Squibb for $14 billion. A successful entrepreneur, Ms. Zohar created PureTech, assembling a leading team to help implement her vision for the company, and was a key driver in fundraising, business development and establishing the underlying programs and platforms that have resulted in PureTech’s productive R&D engine, which led to 28 new medicines being advanced via its Wholly Owned Pipeline and Founded Entities, including Cobenfy (KarXT) that has just received US FDA approval. PureTech’s track record of clinical success is approximately six times better than the industry average and 80 percent of the clinical studies run by PureTech and its Founded Entities have been successful. Ms. Zohar has been recognized as a top leader and innovator in biotechnology by a number of sources, including EY, Goldman Sachs, Fierce Pharma, BioWorld, MIT Technology Review, The Boston Globe and ScientiAmerican. She serves on the BIO (Biotechnology Innovation Organization) Board Executive Committee as well as the Health Section Committee. Ms. Zohar is a member of the Duke-Margolis Center Policy Roundtable on the Inion Reduction Act (IRA) and the Health Affairs IRA Observatory. She is also a co-founder and host of the Biotech Hangout podcast, a weekly discussion of biotech news with a group of industry leaders and experts.